Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Oncotargets and Therapy|April 6, 2026
High-Dose Twice-Daily Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer: A Real-World Retrospective Experience from Two Tertiary CentersOded Icht, Bilal Krayim, Mor Moskovitz, et al.
Frontiers in Oncology|March 16, 2023
Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to OsimertinibWaleed Kian, Bilal Krayim, Hadel Alsana, et al.
Critical Reviews in Oncology/Hematology|July 27, 2024
The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic reviewAreen Abu Remilah, Bilal Krayim, Eitan Amir, et al.
Cancers|June 12, 2026
Surgery After Induction Therapy for Cervical Esophageal Cancer: A Systematic Review and Proposed Multidisciplinary Selection FrameworkIsmaell Massalha, Adham Hijab, Reem Zabit, et al.
Case Reports in Oncology|January 13, 2023
An Unusual Presentation of HCC in a Patient with No Underlying Liver Disease: A Case StudyAnton Osyntsov, Melanie Zemel, Nir Cohen, et al.
Frontiers in Molecular Biosciences|May 11, 2026
Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLCWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Translational Lung Cancer Research|April 18, 2025
Amivantamab as a salvage therapy post-EGFR-tyrosine kinase inhibitor failure in patients with mutated EGFR non-small cell lung cancerBilal Krayim, Waleed Kian, Maria Spector, et al.
Frontiers in Molecular Biosciences|July 9, 2026
Impact of EGFR variant allele frequency on treatment-related adverse events in patients with metastatic NSCLC treated with osimertinibWalid Shalata, Bilal Krayim, Asmah Miari, et al.
Frontiers in Oncology|October 7, 2022
Real-world efficacy and safety of mobocertinib in <i>EGFR</i> exon 20 insertion-mutated lung cancerWaleed Kian, Petros Christopoulos, Areen A Remilah, et al.
International Journal of Radiation Oncology, Biology, Physics|March 16, 2023
Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 StudyNir Peled, Laila C Roisman, Esther Levison, et al.
Pageof 1